Merck’s KEYTRUDA (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma Pharmaceutical Investing
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02 Pharmaceutical Investing
Innovus Pharma Announces the Approval of Its Product ProstaGorx in Canada for Benign Prostatic Hyperplasia Pharmaceutical Investing
Clovis Oncology Submits Application to EMA to Expand Use of Rubraca (rucaparib) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer Biotech Investing
Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018 Biotech Investing
CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting Biotech Investing
New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses Biotech Investing
Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients Pharmaceutical Investing
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab) Pharmaceutical Investing
Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements Pharmaceutical Investing
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients Pharmaceutical Investing
